{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-009922","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2022-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.229055+00:00","generated_at":"2026-06-25T15:14:28.965231+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Eliem Q1 net loss $13.2M; ETX-810 fails DPNP trial; ETX-155 data inconclusive; LSRP data Q3","bullets":["Net loss of $13.2M in Q1 2022 vs $18.6M in Q1 2021; cash $149.9M, funded through at least 2023.","ETX-810 Phase 2a in diabetic peripheral neuropathic pain failed primary endpoint; LSRP trial fully enrolled, topline data Q3 2022.","ETX-155 Phase 1b photosensitive epilepsy interim results inconclusive due to lower exposure; Phase 2a MDD/PMD enrollment delayed pending root cause.","Preclinical Kv7.2/3 channel opener on track for IND-enabling studies in 2022; early anxiolytic program for GAD continues."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-009922","json":"https://secwatch.observer/filing/0000950170-22-009922.json","markdown":"https://secwatch.observer/filing/0000950170-22-009922.md","text":"https://secwatch.observer/filing/0000950170-22-009922.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000095017022009922/0000950170-22-009922-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000095017022009922/elym-20220516.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T15:14:28.965231+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}